Filtering Can Render Donated Blood CMV Seronegative

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

SEATTLE--Filtering donated blood to remove cytomegalovirus (CMV) proved effective in an NIH-funded study from the Fred Hutchinson Cancer Research Center.

SEATTLE--Filtering donated blood to remove cytomegalovirus (CMV)proved effective in an NIH-funded study from the Fred HutchinsonCancer Research Center.

The technique could be a boon to hospitals, which require largequantities of CMV-negative blood for use in immunosuppressed patientsreceiving bone marrow or solid organ transplants and in the smallnumber of AIDS patients who are CMV negative.

Researchers at the Hutchinson Center and the University of Minnesota,in collaboration with the Puget Sound Blood Center, Universityof Minnesota Blood Banks, and St. Paul American Red Cross, tracked502 marrow transplant patients over a 4-year period.

Patients were randomized to receive blood transfusions througha special filter device or blood screened for CMV. The resultsshowed that filtering blood for the virus was as effective asscreening in preventing CMV infections in these patients.

"This is the first time the blood supply has been renderedsafe from a specific infection (CMV) by filtration," sayslead author Dr. Raleigh Bowden, acting director of the InfectiousDiseases Program at Hutchinson.

The finding is especially important, he said, for blood banksin areas such as New York where most potential donors have beenexposed to CMV.

Recent Videos
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
2 experts are featured in this series.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content